NCT02336594View on ClinicalTrials.gov

RDEA3170 Bioavailability Study

PHASE1CompletedINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

November 30, 2014

Primary Completion Date

January 31, 2015

Study Completion Date

March 31, 2015

Conditions
Gout
Interventions
DRUG

RDEA3170 10 mg

DRUG

RDEA3170 2.5 mg

Trial Locations (1)

78744

Austin

Sponsors
All Listed Sponsors
lead

Ardea Biosciences, Inc.

INDUSTRY

NCT02336594 - RDEA3170 Bioavailability Study | Biotech Hunter | Biotech Hunter